Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer

Qu, Tao; Zhang, Jingwen; Xu, Ning; Liu, Bo; Li, Meixiang; Liu, Ailing; Li, Aijun; Tang, Huaping

doi:10.3892/ol.2019.10073

Cited by 15 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With more and more extensive research, it has been found that up‐regulated SCCAg in serum is similarly observed in many malignant tumors such as hepatocellular carcinoma, 29 small cell lung cancer, 13 and esophageal cancer 14 . Among oral malignancies, it has been reported that serum SCCAg levels increase sequentially in the control, OPMD, and OSCC groups 30 .…”

Section: Discussionmentioning

confidence: 99%

“…It often exists in normal squamous epithelial cells but is increased in the serum and tissues of epithelial malignant tumors 12 . Recently, SCCAg has been explored as a biomarker for various malignant diseases such as lung cancer, 13 esophageal cancer, 14 head and neck cancer, 15 and cervical cancer, 16 and has also been explored as a prognostic biomarker for OSCC 17 . A previous study found that SCCAg was elevated in patients with lichen planus and related to the severity of the disease, 18 indicating that it may have a role in the diagnosis and prognosis of OPMDs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of serum synuclein‐γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders

Chen

Luo

Yang

et al. 2020

J Oral Pathology Medicine

View full text Add to dashboard Cite

Background Clinical diagnosis and monitoring are crucial to reduce the mortality from oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs). It has been demonstrated that synuclein‐γ (SNCG) and squamous cell carcinoma antigen (SCCAg) are highly expressed in patients with OSCC and perhaps participate in OSCC progression. This study analyzed the levels of serum SNCG and SCCAg in OSCC, OPMD, and control patients, and evaluated the diagnostic and clinical value of single and combined detection of serum SNCG and SCCAg in OSCC and OPMDs. Patients and methods Serum samples were collected from 197 patients including 87 patients with OSCC, 30 patients with OPMDs, and 80 healthy volunteers as controls. Enzyme‐linked immunosorbent assay and statistical analysis were utilized to determine SNCG and SCCAg levels in serum. Results The levels of SNCG and SCCAg in serum were significantly higher in OSCC compared with OPMDs and controls. There was a correlation between SNCG level and ethnicity, and SCCAg was correlated with differentiation. Furthermore, the area under the curves, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of combined detection of SNCG and SCCAg were better than any single detection. Conclusion The combined detection of SNCG and SCCAg in serum could become a new standard method to distinguish between OSCC and OPMDs and improve diagnostic performance for OSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Assessment of serum synuclein‐γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders

Chen

Luo

Yang

et al. 2020

J Oral Pathology Medicine

View full text Add to dashboard Cite

show abstract

“…The value of the detection of single markers for identifying patients with lung cancer is low; therefore, many others have identified combinations of TAA biomarkers that are useful for detecting LC. Most recently, Qu et al [ 20 ] (Qu, Zhang et al 2019) showed that the combination of thioredoxin (Trx), CYFRA21-1, and SCC biomarkers can improve both specificity and sensitivity to diagnose lung cancer patients from healthy subjects. Jiang et al [ 21 ] (Jiang, Wang et al 2018) investigated a combination of CEA, CYFRA21, NSE, and thymidine kinase 1 (TK1) for lung cancer diagnosis; the results showed that the diagnostic value of TK1 combined with CEA, CYFRA21-1, and NSE was significantly higher than that of each biomarker alone.…”

Section: Discussionmentioning

confidence: 99%

Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis

et al. 2020

View full text Add to dashboard Cite

Background. Lung cancer (LC) is top-ranked in cancer incidence and is the leading cause of cancer death globally. Combining serum biomarkers can improve the accuracy of LC diagnosis. The identification of the best potential combination of traditional tumor markers is essential for LC diagnosis. Patients and Methods. Blood samples were collected from 132 LC cases and 118 benign lung disease (BLD) controls. The expression levels of ten serum tumor markers (CYFR21, CEA, NSE, SCC, CA15-3, CA 19-9, CA 125, CA50, CA242, and CA724) were assayed, and that the expression in the levels of tumor markers were evaluated, isolated, and combined in different patients. The performance of the biomarkers was analyzed by receiver operating characteristic (ROC) analyses, and the difference between combinations of biomarkers was compared by Chi-square ( χ 2 ) tests. Results. As single markers, CYFR21 and CEA showed good diagnostic efficacy for nonsmall cell lung cancer (NSCLC) patients, while NSE and CEA were the most sensitive in the diagnosis of small cell lung cancer (SCLC). The area under the curve (AUC) value was 0.854 for the panel of four biomarkers (CYFR21, CEA, NSE, and SCC), 0.875 for the panel of six biomarkers (CYFR21, CEA, NSE, SCC, CA125, and CA15-3), and 0.884 for the panel of ten markers (CYFR21, CEA, NSE, SCC, CA125, CA15-3, CA19-9, CA50, CA242, and CA724). With a higher sensitivity and negative predictive value (NPV), the diagnostic accuracy of the three panels was better than that of any single biomarker, but there were no statistically significant differences among them (all P values > 0.05). However, the panel of six carbohydrate antigen (CA) biomarkers (CA125, CA15-3, CA19-9, CA50, CA242, and CA724) showed a lower diagnostic value (AUC: 0.776, sensitivity: 59.8%, specificity: 73.0%, and NPV: 60.4%) than the three panels ( P value < 0.05). The performance was similar even when analyzed individually by LC subtypes. Conclusion. The biomarkers isolated are elevated for different types of lung cancer, and the panel of CYFR21, CEA, NSE, and SCC seems to be a promising serum biomarker for the diagnosis of lung cancer, while the combination with carbohydrate antigen markers does not improve the diagnostic efficacy.

show abstract

“…To improve the diagnostic accuracy and avoid unnecessary invasive procedures, it was necessary to combine tumor markers with imaging. The conventional serum biomarkers for lung cancer included cytokeratin 19 (CYFRA21‐1), pro‐gastrin‐releasing‐peptide (ProGRP), carcinoembryonic antigen (CEA) neuron‐specific enolase (NSE), and squamous cell carcinoma‐associated antigen (SCCA) 10,11 . Study 12 indicated that for solitary pulmonary lesions, using the tumor markers alone, the highest sensitivity (27.2%) and accuracy (40.4%) were found with CEA, the highest specificity (100%) with CYFRA 21‐1, and with NSE.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic value of conventional tumor markers in young patients with pulmonary nodules

Xie

2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Lung cancer is one of the most common malignancies, and there is a trend of increasing incidence in young patients. The preoperative diagnosis of pulmonary nodules is mainly based on the combination of imaging and tumor markers. There is no relevant report on the diagnostic value of tumor markers in young pulmonary nodules. Our study was designed to explore the value of five tumor markers in young patients with pulmonary nodules. Methods We reviewed the medical records of 390 young patients (age ≤45 years) with pulmonary nodules treated at two separate centers from January 1, 2015, to January 1, 2021. Malignant pulmonary nodules were confirmed in 318 patients, and the other 72 patients were diagnosed with benign pulmonary nodules. The gold standard for diagnosis of pulmonary nodules was surgical biopsy. The conventional serum biomarkers included cytokeratin 19 (CYFRA21‐1), pro‐gastrin‐releasing‐peptide (ProGRP), carcinoembryonic antigen (CEA), neuron‐specific enolase (NSE), and squamous cell carcinoma‐associated antigen (SCCA). The diagnostic values of five tumor markers were analyzed by receiver operating characteristic (ROC) curves. Results There were no significant differences in the expression of five tumor markers between the groups (p > 0.05). Single tumor marker (CYFRA21‐1, ProGRP, CEA, NSE, and SCCA) showed a limited value in the diagnosis of malignant pulmonary nodules, with the AUC of 0.506, 0.503 0.532, 0.548, and 0.562, respectively. The AUC of the combined examination was only 0.502~0.596, which did not improve the diagnostic value. Conclusions Five conventional tumor markers had a limited diagnostic value in young patients with pulmonary nodules.

show abstract

Diagnostic value analysis of combined detection of Trx, CYFRA21-1 and SCCA in lung cancer

Cited by 15 publications

References 18 publications

Assessment of serum synuclein‐γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders

Assessment of serum synuclein‐γ and squamous cell carcinoma antigen as diagnostic biomarkers in patients with oral squamous cell carcinoma and oral potentially malignant disorders

Lack of Efficacy of Combined Carbohydrate Antigen Markers for Lung Cancer Diagnosis

Diagnostic value of conventional tumor markers in young patients with pulmonary nodules

Contact Info

Product

Resources

About